nodes	percent_of_prediction	percent_of_DWPC	metapath
Clenbuterol—NGF—autonomic nervous system—Gilles de la Tourette syndrome	0.387	0.67	CbGeAlD
Clenbuterol—NGF—nervous system—Gilles de la Tourette syndrome	0.049	0.0848	CbGeAlD
Clenbuterol—NGF—central nervous system—Gilles de la Tourette syndrome	0.0471	0.0816	CbGeAlD
Clenbuterol—NGF—brain—Gilles de la Tourette syndrome	0.0374	0.0648	CbGeAlD
Clenbuterol—ADRB3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0205	0.0486	CbGpPWpGaD
Clenbuterol—ADRB3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0175	0.0415	CbGpPWpGaD
Clenbuterol—ADRB3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.017	0.0402	CbGpPWpGaD
Clenbuterol—ADRB3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0158	0.0375	CbGpPWpGaD
Clenbuterol—ADRB3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0147	0.0349	CbGpPWpGaD
Clenbuterol—ADRB3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0143	0.0338	CbGpPWpGaD
Clenbuterol—ADRB3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0133	0.0315	CbGpPWpGaD
Clenbuterol—ADRB1—nervous system—Gilles de la Tourette syndrome	0.0127	0.0221	CbGeAlD
Clenbuterol—ADRB1—central nervous system—Gilles de la Tourette syndrome	0.0123	0.0212	CbGeAlD
Clenbuterol—ADRB1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0122	0.0289	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0119	0.0282	CbGpPWpGaD
Clenbuterol—TNF—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.0116	0.0275	CbGpPWpGaD
Clenbuterol—ADRB3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0111	0.0263	CbGpPWpGaD
Clenbuterol—ADRB1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0104	0.0246	CbGpPWpGaD
Clenbuterol—ADRB2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0102	0.0241	CbGpPWpGaD
Clenbuterol—ADRB1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0101	0.0239	CbGpPWpGaD
Clenbuterol—ADRB2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00987	0.0234	CbGpPWpGaD
Clenbuterol—ADRB1—brain—Gilles de la Tourette syndrome	0.00975	0.0169	CbGeAlD
Clenbuterol—ADRB1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0094	0.0223	CbGpPWpGaD
Clenbuterol—ADRB3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00932	0.0221	CbGpPWpGaD
Clenbuterol—ADRB2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00919	0.0218	CbGpPWpGaD
Clenbuterol—ADRB1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00873	0.0207	CbGpPWpGaD
Clenbuterol—ADRB2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00854	0.0202	CbGpPWpGaD
Clenbuterol—ADRB1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00848	0.0201	CbGpPWpGaD
Clenbuterol—ADRB2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00829	0.0196	CbGpPWpGaD
Clenbuterol—CYP1A1—nervous system—Gilles de la Tourette syndrome	0.00822	0.0142	CbGeAlD
Clenbuterol—CYP1A1—central nervous system—Gilles de la Tourette syndrome	0.00792	0.0137	CbGeAlD
Clenbuterol—ADRB1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0079	0.0187	CbGpPWpGaD
Clenbuterol—ADRB2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00773	0.0183	CbGpPWpGaD
Clenbuterol—ADRB1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00658	0.0156	CbGpPWpGaD
Clenbuterol—ADRB2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00644	0.0152	CbGpPWpGaD
Clenbuterol—CYP1A1—brain—Gilles de la Tourette syndrome	0.00628	0.0109	CbGeAlD
Clenbuterol—NGF—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00619	0.0146	CbGpPWpGaD
Clenbuterol—ADRB1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00553	0.0131	CbGpPWpGaD
Clenbuterol—ADRB2—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.00547	0.013	CbGpPWpGaD
Clenbuterol—ADRB2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00541	0.0128	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00451	0.0107	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00438	0.0104	CbGpPWpGaD
Clenbuterol—ADRB3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00338	0.008	CbGpPWpGaD
Clenbuterol—ADRB3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00328	0.00777	CbGpPWpGaD
Clenbuterol—ADRB3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00306	0.00724	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00289	0.00685	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00286	0.00677	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00281	0.00665	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00262	0.0062	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00225	0.00533	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.0022	0.00522	CbGpPWpGaD
Clenbuterol—ADRB3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00214	0.00507	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00214	0.00507	CbGpPWpGaD
Clenbuterol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00201	0.00475	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00199	0.00472	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00196	0.00465	CbGpPWpGaD
Clenbuterol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00195	0.00461	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0019	0.00451	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00183	0.00434	CbGpPWpGaD
Clenbuterol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00181	0.00429	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00177	0.0042	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00172	0.00407	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00168	0.00398	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00167	0.00395	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00163	0.00386	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00155	0.00368	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00152	0.0036	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.0014	0.00331	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00131	0.0031	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00129	0.00306	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00128	0.00303	CbGpPWpGaD
Clenbuterol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00127	0.00301	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00127	0.00301	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00125	0.00297	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00125	0.00295	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00124	0.00294	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00124	0.00294	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00121	0.00286	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00118	0.0028	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00117	0.00277	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00116	0.00274	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00113	0.00268	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00113	0.00267	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.0011	0.0026	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00109	0.00258	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00106	0.00252	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00102	0.00242	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000829	0.00196	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000818	0.00194	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000816	0.00193	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000811	0.00192	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000798	0.00189	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000789	0.00187	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000739	0.00175	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000723	0.00171	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000718	0.0017	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000716	0.0017	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000702	0.00166	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000671	0.00159	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000669	0.00158	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000668	0.00158	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000657	0.00156	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000654	0.00155	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000652	0.00154	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000649	0.00154	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000638	0.00151	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000607	0.00144	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000604	0.00143	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000594	0.00141	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000521	0.00123	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000468	0.00111	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000458	0.00108	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000425	0.00101	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000423	0.001	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000416	0.000985	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000397	0.000939	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000388	0.000919	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000385	0.000912	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000377	0.000892	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000359	0.000849	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000351	0.000831	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000251	0.000595	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000246	0.000582	CbGpPWpGaD
